Contact our experts
Select another language
World
World
ENFRESITDE
Select another language
World
World
ENFRESITDE

Pricing and Reimbursement dossiers UK

Welcome to Justin Stindt Consultants, your premier agency specializing in pricing & reimbursement dossiers UK. In the UK’s dynamic pricing and reimbursement landscape, cost-effectiveness is paramount, with a focus on quality-adjusted-life-years (QALY) as a key determinant. Our international team of experts is adept at navigating the intricate pathways of NICE, SMC, and AWMSG submissions, ensuring your pharma, biotech, or medtech products are positioned optimally within Great Britain’s healthcare system. As a global consulting agency, we emphasize the importance of articulating the cost-effectiveness of your product for successful market entry in England, Scotland, Wales, and Northern Ireland. Trust in Justin Stindt Consultants to be your partner in ensuring your submissions resonate with precision, clarity, and evidence-based narratives in the UK’s evolving market access framework.

Understanding NICE and SMC HTA Submissions: Key Determinants in UK's Drug Pricing and Reimbursement Landscape

Cost-effectiveness / cost-utility is the key determinant in the United Kingdom pricing & reimbursement landscape and costly drugs usually enter the market through various commercial arrangements. The cost-utility assessment hinges on the quality-adjusted-life-years (QALY) contributed by the medicine. A QALY, the product of life expectancy and a measure of the quality of the remaining years of life, considers the quantity and the quality of life generated by healthcare interventions.

Pricing and Reimbursement dossiers UK
In England, National Institute for Health and Care Excellence (NICE) Technology appraisals, are recommendations on the use of new and existing medicines, medical devices, diagnostic techniques, surgical procedures, or health promotion activities within the National Health Service (NHS). These appraisals take one of 3 forms: single technology appraisal (STA), fast track appraisal (FTA) or multiple technology appraisal (MTA). The NHS is legally obliged to fund and provide access to medicines and treatments recommended by NICE’s technology appraisals. NICE covers England and Wales, although Wales also has the AWMSG, which defers to NICE on evaluations but can provide additional guidance to pharmaceutical, biotech and medtech companies wishing to enter the UK market. In Scotland, the Scottish Medicines Consortium issues advice on all new active substances and all new indications for established products either through the full submission process, or the abbreviated submission when:
  1. There are alternatives within the same therapeutic class that have previously been accepted for use, OR
  2. a low net budget impact is expected

Why Choose Justin Stindt Consultants for your pricing and reimbursement dossier in the UK?

Pricing and Reimbursement Dossiers Consulting Agency United-Kingdom

Justin Stindt Consultants is an agency specialized in UK HTA dossiers for NICE, SMC and AWMSG. Our experienced team of consultants and experts will help you to articulate the cost-effectiveness of your product in the UK HTA dossiers.

Our company’s commitment lies in delivering HTA submissions that excel in written excellence, technical precision, and the art of weaving clear, captivating narratives. Our goal as a consulting agency is to ensure that each submission forms a cohesive, integrated, evidence-based story, moving away from a mere assortment of distinct clinical and health-economic elements typically found in an evidence package.

Our specialists hold a comprehensive understanding of the specific requirements outlined by NICE, the SMC, and AWMSG, which will help you enter the UK pharmaceutical market. Our firm partners with leading health economists to provide expertise and advice feeding into the model and dossier development.

Justin Stindt Consultants is your international agency with the right experts in supporting the preparation of NICE, AWMSG and SMC HTA submissions. Our services include (not limited to):

  • Comprehensive project planning with clear timelines and milestones
  • Strategic review of drug positioning
  • Health Economic Modeling
  • Dossier writing, both English originals and if required translations
  • Dossier validation with Key Opinion Leaders, Health Economists and ex-members of NICE, AWMSG and SMC
  • Submission process guidance and support
  • Hearing preparation and support
  • Strategic advice and participation in price negotiations
  • Effective project management and communication throughout the process

At Justin Stindt Consultants, our team of experts has extensive experience in providing our firm’s clients with tailored support to provide access to patients in the UK as soon as possible at sustainable pricing and reimbursement conditions. If you are looking for a vendor to support your UK dossiers, select a service provider that will go the extra mile to enable HTA endorsement for your product.

Let Justin Stindt Consultants be your trusted global agency partner in unlocking pricing & reimbursement (P&R) opportunities for your product in the UK.

Contact us today to learn how we can tailor our services to meet your unique needs and make your pricing & reimbursement goals a reality.

Meet one of our Pricing and Reimbursement dossiers UK experts

Justin Stindt
Having worked on many projects in the UK market, Justin understands the dynamics of the UK P&R landscape and the importance of cost-effectiveness models. In previous projects he has interacted extensively with UK authorities (NICE, SMC, AWMSG) to ensure dossier support the optimal positioning of pharma, biotech and medtech clients within the UK healthcare system.

Get in touch with our expert

Connect with our team

Our experienced Market Access specialists are just a click away

Contact Us

CLIENT TESTIMONIALS

It is a pleasure collaborating with Justin Stindt Consulting. Their professionalism and ease of communication have significantly enhanced our projects. Their team possesses deep knowledge in EU HTA processes, making them an invaluable asset in navigating complex national reimbursement landscapes. Their commitment to excellence and collaboration is truly commendable.
Peter Foertig
VP Medical Affairs Europe Taiho Oncology Europe GmbH
Justin and his team have been instrumental in gaining patient access and reimbursement for our drug in a number of EU countries. Through Justin’s expertise and his extensive network across the EU, he has also been able to apply the appropriate skills and knowledge to select EU countries where reimbursement is feasible. Ultimately, Justin’s work has enabled patients with a serious, rare disease to receive access to a life extending treatment while establishing a competitive price and gaining reimbursement for the company.
Eldon Mayer
Chief Commercial Officer Eiger Biopharmaceuticals
I had multiple opportunities to work with Justin and his consulting team and the collaboration has always been extremely positive. Justin Consulting is a boutique consulting company, they combine technical mastery, experience and the ability to tailor their service to the client needs. The short line of communication makes also easy to brainstorm with them on strategic topics, being sure that the most senior Consultants are personally involved. Finally, all the people I have worked with, and especially Justin, are always available, enjoyable and open so that working with them is a real pleasure.
Silvia Chiroli
Head of Market Access EMEA & CM Italy at argenx
Read all testimonials
Global Pricing & Reimbursement
Pricing & Reimbursement Submissions
Payer & HTA engagement
Get Updates And Stay Connected -Subscribe To Our Newsletter
Justin Stindt Logo

Pharma Market Access Agency

Justin Stindt Consultants is a fast growing consulting company offering strategy & market access consulting services to leading pharmaceutical, biotech and medical device clients. We operate in Europe and the United States.

Read More

Contact Our Company

News

© 2024 Justin Stindt Consultants a Brand of Justin Stindt Consulting

Select another language
World
World
ENFRESITDE
X-twitter Facebook-f Youtube